Natera Reports First Quarter 2024 Financial Results
Natera Inc NTRA
News
-
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
Natera to Report its First Quarter 2024 Results on May 9
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
Natera to Participate in March Investor Conferences
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call